Search results
Results From The WOW.Com Content Network
Pfizer (PFE) suffers massively in 2019 due to aggressive business development activity, incremental currency woes and loss of exclusivity of key drug Lyrica. But it is poised to have a better 2020.
This past year wasn't a great one for Pfizer (NYSE:PFE) stock. While the S&P 500 soared 29%, shares in the pharma giant fell to $39.18 per share, making for a 9.1% loss. The reason? Wall Street ...
AlamyBy Arthur Allen | KHNThe grinding two-plus years of the pandemic have yielded outsize benefits for one company—Pfizer—making it both highly influential and hugely profitable as covid-19 ...
The following table lists the largest biotechnology and pharmaceutical companies ranked by revenue in billion USD. The change column indicates the company's relative position in this list compared to its relative position in the preceding year; i.e., an increase would be moving closer to rank 1 and vice versa.
Despite constant attempts by analysts and the media to complicate the basics of investing, there are really only three ways a stock can create value for its shareholders: Dividends. Earnings growth.
Pfizer's (PFE) fourth-quarter earnings and sales beat estimates. Its forecast for 2019 falls short of expectations. Stock dips 2% in pre-market trading.
For premium support please call: 800-290-4726 more ways to reach us
Pfizer last year renegotiated a U.S. contract, allowing the government to return unused Paxlovid inventory. It recorded a $771 million favorable adjustment in the quarter, related to the U.S ...